- Home
- KLRS vs REFR Comparison
KLRS vs REFR Comparison
Compare KLRS & REFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- REFR
- Stock Information
- Founded
- KLRS 2019
- REFR 1965
- Country
- KLRS United States
- REFR United States
- Employees
- KLRS N/A
- REFR N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- REFR Multi-Sector Companies
- Sector
- KLRS Health Care
- REFR Miscellaneous
- Exchange
- KLRS Nasdaq
- REFR Nasdaq
- Market Cap
- KLRS 46.0M
- REFR 49.5M
- IPO Year
- KLRS N/A
- REFR N/A
- Fundamental
- Price
- KLRS $2.56
- REFR $1.40
- Analyst Decision
- KLRS Buy
- REFR
- Analyst Count
- KLRS 1
- REFR 0
- Target Price
- KLRS N/A
- REFR N/A
- AVG Volume (30 Days)
- KLRS 45.1K
- REFR 34.8K
- Earning Date
- KLRS 08-13-2025
- REFR 08-07-2025
- Dividend Yield
- KLRS N/A
- REFR N/A
- EPS Growth
- KLRS N/A
- REFR N/A
- EPS
- KLRS N/A
- REFR N/A
- Revenue
- KLRS N/A
- REFR $1,222,239.00
- Revenue This Year
- KLRS N/A
- REFR N/A
- Revenue Next Year
- KLRS N/A
- REFR N/A
- P/E Ratio
- KLRS N/A
- REFR N/A
- Revenue Growth
- KLRS N/A
- REFR N/A
- 52 Week Low
- KLRS $2.14
- REFR $0.93
- 52 Week High
- KLRS $24.15
- REFR $2.38
- Technical
- Relative Strength Index (RSI)
- KLRS 49.38
- REFR 35.41
- Support Level
- KLRS $2.37
- REFR $1.37
- Resistance Level
- KLRS $2.58
- REFR $1.45
- Average True Range (ATR)
- KLRS 0.18
- REFR 0.07
- MACD
- KLRS 0.01
- REFR -0.01
- Stochastic Oscillator
- KLRS 64.32
- REFR 11.20
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.